Table 4.
Results of budget impact analysis
| Year | Budget impact: total additional expenditure (¥, million) | Additional expenditure for screening (¥, million) | Additional expenditure for curative care (¥, million) | |||
|---|---|---|---|---|---|---|
| Policy 1: mandate serum Cr assay | Policy 2: mandate serum Cr assay and abandon dipstick test | Policy 1: mandate serum Cr assay | Policy 2: mandate serum Cr assay and abandon dipstick test | Policy 1: mandate serum Cr assay | Policy 2: mandate serum Cr assay and abandon dipstick test | |
| 1st (2012) | 975 | 963 | 2 | −10 | 973 | 973 |
| 2nd (2013) | 1,362 | 1,349 | 2 | −10 | 1,360 | 1,359 |
| 3rd (2014) | 1,705 | 1,692 | 2 | −10 | 1,704 | 1,702 |
| 4th (2015) | 2,011 | 1,998 | 2 | −10 | 2,010 | 2,008 |
| 5th (2016) | 2,287 | 2,274 | 2 | −10 | 2,285 | 2,284 |
| 6th (2017) | 2,537 | 2,523 | 2 | −10 | 2,535 | 2,533 |
| 7th (2018) | 2,765 | 2,751 | 2 | −10 | 2,763 | 2,761 |
| 8th (2019) | 2,973 | 2,958 | 2 | −10 | 2,971 | 2,969 |
| 9th (2020) | 3,164 | 3,149 | 2 | −10 | 3,162 | 3,159 |
| 10th (2021) | 3,342 | 3,328 | 2 | −10 | 3,341 | 3,338 |
| 11th (2022) | 3,513 | 3,498 | 2 | −10 | 3,511 | 3,508 |
| 12th (2023) | 3,677 | 3,662 | 2 | −10 | 3,675 | 3,672 |
| 13th (2024) | 3,833 | 3,818 | 2 | −10 | 3,832 | 3,828 |
| 14th (2025) | 3,983 | 3,967 | 2 | −10 | 3,981 | 3,977 |
| 15th (2026) | 4,129 | 4,113 | 2 | −10 | 4,127 | 4,123 |
Cr creatinine